172939-25-2

Upstream product

• 58990-26-4 methyl 4-deoxy-β-L-erythro-pentopyranoside 
• 172939-21-8 2,3-di-O-benzyl-4-deoxy-L-erythro-pentose trimethylene dithioacetal 
• 173008-87-2 Acetic acid (3S,4R,5S)-3,4-bis-benzyloxy-6,6,6-trifluoro-5-hydroxy-hexyl ester 
• 1054656-97-1 Acetic acid (3S,4S,5S)-3,4-bis-benzyloxy-6,6,6-trifluoro-5-trifluoromethanesulfonyloxy-hexyl ester 
• 172939-22-9 5-O-acetyl-2,3-di-O-benzyl-4-deoxy-L-erythro-pentose trimethylene dithioacetal 
• 172939-23-0 5-O-acetyl-2,3-di-O-benzyl-4-deoxy-aldehydo-L-erythro-pentose 
• 172939-18-3 methyl 2,3-di-O-benzyl-4-deoxy-β-L-erythro-pentopyranoside 
• 100-39-0 benzyl bromide 
• 172939-24-1 6-O-acetyl-3,4-di-O-benzyl-1,5-dideoxy-1,1,1-trifluoro-L-arabino-hexitol 

Downstream Products

• 188892-82-2 C₂₆H₃₉F₃O₄Si₂ 

Relevant academic research and scientific papers

Anthracycline derivative having a trifluoromethylated sugar

Novel anthracycline derivatives have now been produced, which exhibit higher antitumor activities and lower toxicities than those of daunomycin, adriamycin etc. that have been clinically used as anticancer agents. That is, a daunomycinone or adriamycinone

A 5′-(trifluoromethyl)anthracycline glycoside: Synthesis of antitumor-active 7-O-(2,6-dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl)adriamycinone

7-O-(2,6-Dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl)adriamycinone (3), whose substituent at C-5′ is a lipophilic trifluoromethyl group, has been prepared by coupling of 3,4-di-O-acetyl-2,6-dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl bromide (20) wi